CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing therapy for sickle cell disease. Reimbursement and access for Casgevy now ...
Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...
JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing ...
Hazelton confirmed Dyadic expects momentum to build with additional product opportunities in 2025, accelerating in 2026 as the company scales its portfolio and expands its global market reach. He ...
CRISPR Therapeutics' first approval should go on to become massively successful. This approval was a major breakthrough in the area of gene editing. CRISPR Therapeutics has some qualities that could ...
* Maxcyte will supply systems Co and Casebia as part of license agreement and will receive upfront, milestone, and sales-based payments * Says commercial license builds on an existing research and ...
Crispr Therapeutics AG's current revenue from CASGEVY is limited by high costs, profit-sharing, and logistical hurdles, making future pipeline progress critical. Management is focused on improving ...
New Early Access Express License provides streamlined, affordable access to foundational CRISPR/Cas9 intellectual property to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results